Psychiatric Times

05/25/2026

This Memorial Day, Psychiatric Times honors the brave individuals who made the ultimate sacrifice in service to our country. We remember their courage, reflect on their legacy, and express gratitude to all who have served.

05/22/2026

🎙️🧐💊 This week's "Brain Trust" episode is now live!

Guest Michael Gitlin, MD, shares insights on the complex psychopharmacology of personality disorders:

Explore psychopharmacologic options for personality disorders in this podcast.

05/22/2026

Antipsychotic medications are the cornerstone of treatment and remain the most effective intervention for reducing psychotic symptoms and preventing relapse. Yet medication alone is often insufficient. Psychotherapy, when integrated thoughtfully with biological treatment, can play an important role in relapse prevention and long-term recovery.

Read more from Mark L. Ruffalo and Trisha Ruffalo, LCSW here: https://www.psychiatrictimes.com/view/psychotherapy-and-the-prevention-of-relapse-in-schizophrenia

05/21/2026

The HHS has released the Surgeon General’s “Warning on the Harms of Screen Use," which aims to raise national awareness about the growing risks associated with excessive and harmful screen use among youth.

New Surgeon General advisory warns of youth screen and social media harms, urging families, schools, and clinicians to act with the 5 Ds.

05/21/2026

Need new reading material? The entire May 2026 issue of Psychiatric Times is now live on our website. Read it here: https://www.psychiatrictimes.com/journals/psychiatric-times/vol-43-issue-5

05/20/2026

The latest focus on psychedelic use for mood disorders and continued research into neuromodulation holds much potential, says Gus Alva, MD. https://www.psychiatrictimes.com/shorts/future-of-psychedelics-and-brain-stimulation

05/20/2026

Ketamine-assisted psychotherapy may have a practical advantage over psilocybin, M**A, and LSD-assisted protocols, which typically require 6 to 10 hours per session, compared with approximately 2 hours for ketamine-assisted psychotherapy, shared Fernando Espí Forcén. https://www.psychiatrictimes.com/view/advances-in-ketamine-assisted-psychotherapy

05/20/2026

Behavioral addictions extend beyond traditional internet overuse and may include compulsive gaming, extreme online gambling, and even maladaptive exercise behaviors shaped by social media culture, shared Hector Colon-Rivera, MD, MBA, MRO, FAPA. https://www.psychiatrictimes.com/view/assessing-and-treating-digital-behavioral-addictions-insights-at-apa

05/20/2026

Christoph Correll, MD, presented efficacy and real-world data on olanzapine-samidorphan for schizophrenia and bipolar disorder at

He found that it keeps olanzapine efficacy yet limits weight gain, improves negative symptoms, and cuts ER visits in real-world care. https://www.psychiatrictimes.com/view/olanzapine-samidorphan-for-schizophrenia-new-real-world-adherence-data

05/20/2026

Synendos Therapeutics has initiated dosing in a phase 2 trial of SYT-510, a first-in-class endocannabinoid modulator, aiming to ease generalized anxiety disorder symptoms with improved safety and adherence. https://www.psychiatrictimes.com/view/syt-510-for-generalized-anxiety-disorder-phase-2-trial-dosing-initiated